Citadel Advisors
TPTX

Citadel Advisors’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Citadel Advisors’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-165,650
Closed -$12.5M – 14227
2022
Q2 		$12.5M Sell
165,650
-661,192
-80% -$29.4M ﹤0.01% 2397
2022
Q1 		$22.2M Buy
826,842
+180,616
+28% +$6.07M ﹤0.01% 1864
2021
Q4 		$30.8M Buy
646,226
+404,278
+167% +$18.1M 0.01% 1575
2021
Q3 		$16.1M Buy
241,948
+234,856
+3,312% +$16.7M ﹤0.01% 2322
2021
Q2 		$554K Sell
7,092
-96,894
-93% -$7.16M ﹤0.01% 9840
2021
Q1 		$9.84M Buy
103,986
+97,652
+1,542% +$11.6M ﹤0.01% 2985
2020
Q4 		$772K Sell
6,334
-96,388
-94% -$10.6M ﹤0.01% 7324
2020
Q3 		$8.97M Buy
102,722
+51,481
+100% +$3.59M ﹤0.01% 2413
2020
Q2 		$3.31M Buy
51,241
+39,328
+330% +$2.27M ﹤0.01% 3692
2020
Q1 		$532K Buy
+11,913
New +$633K ﹤0.01% 6370
2019
Q3 		– Sell
-45,541
Closed -$1.85M – 9971
2019
Q2 		$1.85M Buy
+45,541
New +$1.62M ﹤0.01% 4638

Citadel Advisors's TPTX Position: Q3 2022 in Review

Citadel Advisors sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 165,650 shares — an estimated $12.5M sold.

Citadel Advisors first reported a position in TPTX in Q2 2019 and held it in 11 quarters. The position peaked at $30.8M in Q4 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Citadel Advisors reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Citadel Advisors sold 165,650 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $12.5M.
  • Citadel Advisors first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 11 quarters.
  • Citadel Advisors's Turning Point Therapeutics, Inc. Common Stock position peaked at $30.8M in Q4 2021.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.